Amendments to the Claims:

This following listing of claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1.-24. (Cancelled)

25. (New) A transmembrane delivery system comprising one or more than one amphipathic ionic compound in monomeric form, and one or more than one polar ionizable agent of interest.

26. (New) The delivery system of claim 25, wherein said amphipathic ionic compound is an ionic surfactant or mixture of ionic surfactants selected from the group consisting of anionic surfactants, cationic surfactants and zwitterionic surfactants, said ionic surfactants capable of forming reverse micelles.

27. (New) The delivery system of claim 25, wherein the one or more than one amphipathic ionic compound and the one or more than one polar ionizable agent of interest are oppositely charged.

28. (New) The delivery system of claim 25, wherein said amphipathic ionic compound comprises an anionic surfactant capable of forming reverse micelles.

29. (New) The delivery system of claim 25, wherein said amphipathic ionic compound comprises a cationic surfactant capable of forming reverse micelles.

30. (New) The delivery system of claim 25, wherein said agent of interest has a partition coefficient between water and octanol at pH 7.4 of less than about 10.

31. (New) The delivery system of claim 25, wherein said amphipathic ionic compound is present in an amount of about 0.5 weight % to about 500 weight %.

32. (New) The delivery system of claim 25, wherein said agent of interest comprises a therapeutically active compound of a Class III biopharmaceutical.

33. (New) The delivery system of claim 25, wherein the agent of interest comprises a plurality of discrete active particulates.

34. (New) The delivery system of claim 26, wherein the anionic surfactant is selected from the group consisting of sodium dodecyl sulfate, potassium dodecyl sulfate, sodium octadecylsulfate, sodium bis(2-ethylhexyl) sulfosuccinate (AOT), and a combination thereof.

35. (New) The delivery system of claim 26, wherein the cationic surfactant is selected from the group consisting of didodecyl dimethyl ammonium bromide (DDAB), cetyl-triammonium bromide (CTAB), cetylpyridinium bromide (CPB), dodecyl trimethyl ammonium chloride (DOTAC), sodium perfluorononanoate (SPFN), hexadecyl trimethyl ammonium bromide (HDTMA), and a combination thereof.

36. (New) The delivery system of claim 26, formulated as a solid tablet, a matrix tablet, granules or a capsule.

37. (New) The delivery system of claim 26, further comprising one or more than one pharmaceutically acceptable excipient.

38. (New) The delivery system of claim 26, wherein the delivery system is in the form of one of a matrix solid compact, made by a compression or pelletization method, and a matrix extrusion spheroid, made by a wet or dry extrusion method.

39. (New) The delivery system of claim 26, wherein the delivery system is granulated or microencapsulated to form particulates that may be compressed into solid compacts or filled into capsules.

40. (New) The delivery system of claim 26, wherein the delivery system is in a dosage form selected from the group consisting of granulated, particulate, spheroidal, compact and dry blends, and wherein the delivery system can be filled into capsules or suspended in a suitable liquid vehicle.

41. (New) The delivery system of claim 37, wherein said one, or more than one pharmaceutically acceptable excipient is one, or more than one compound selected from the group consisting of: one, or more than one viscosity enhancer; one, or more than one enteric polymer; one, or more than one pH-specific barrier polymer; one, or more than one diluent; one, or more than one anti-adherent; one, or more than one glidant; one, or more than one binder; one, or more than one solubilizer; one, or more than one channeling agent; one, or more than one wetting agent; one, or more than one buffering agent; one, or more than one flavourant; one, or more than one adsorbent; one, or more than one sweetening agent; one, or more than one colorant; one, or more than one lubricant; and a combination thereof.

42. (New) The delivery system of claim 25, wherein the one, or more than one agent of interest is one, or more than one compound selected from the group consisting of one, or more than one analgesic; one, or more than one anti-inflammatory; one, or more than one antimicrobial; one, or more than one amoebicidal; one, or more than one trichomonocidal agent; one, or more than one anti-Parkinson; one, or more than one anti-malarial; one, or more than one anticonvulsant; one, or more than one anti-depressant; one, or more than one anti-arthritic; one, or more than one anti-fungal; one, or more than one antihypertensive; one, or more than one antipyretic; one, or more than one anti-parasite; one, or more than one antihistamine; one, or more than one alpha-adrenergic agonist; one, or more than one alpha blocker; one, or more than one anaesthetic; one, or more than one bronchial dilator; one, or more than one biocide; one, or more than one bactericide; one, or more than one bacteriostat; one, or more than one beta adrenergic blocker; one, or more than one calcium channel blocker; one, or more than one cardiovascular drug; one, or more than one contraceptive; one, or more than one decongestant; one, or more than one diuretic; one, or more than one depressant; one, or more than one diagnostic; one, or more than one electrolyte; one, or more than one hypnotic; one, or more than one hormone; one, or more than one hyperglycaemic; one, or more than one muscle relaxant; one, or more than one muscle

contractant; one, or more than one ophthalmic; one, or more than one parasympathomimetic; one, or more than one psychic energizer; one, or more than one sedative; one, or more than one sympathomimetic; one, or more than one tranquilizer; one, or more than one viricide; one, or more than one vitamin; one, or more than one non-steroidal anti-inflammatory; one, or more than one angiotensin converting enzyme inhibitor; one, or more than one polypeptide; one, or more than one protein; one, or more than one sleep inducer; and a combination thereof.

43. (New) A method of delivering a therapeutic agent to a subject in need thereof, comprising:

i) formulating the delivery system of claim 25, wherein the agent of interest comprises a therapeutic agent, and

ii) administering said delivery system to a subject in need thereof.

44. (New) The method of claim 43, wherein said administering comprises oral administration.